Tumor targeting antibodies bridge innate to adaptive immunity. Yang-Xin Fu MD PhD Professor of Pathology and Immunology UT Southwestern
|
|
- Jessica Horton
- 5 years ago
- Views:
Transcription
1 Tumor targeting antibodies bridge innate to adaptive immunity Yang-Xin Fu MD PhD Professor of Pathology and Immunology UT Southwestern
2 Tumor targeting antibodies are screened and selected to kill tumor cells Tumor targeting antibodies oncogenic receptors: anti-her2/neu CD2 (cell lineage) CD47 (do not eat me signal) Bi-specific antibody: increase efficacy and reduce toxicity 2
3 How can anti-her2/neu antibody reduce tumor burden: complex mechanisms? Oncogenic blockade vs FcR mediated kill? NK TUMOR We select WT vs Rag-1 KO mice for stronger ADCC but lack T /B cells to test its impact TUMOR 3
4 Tumor volume (mm 3 ) Tumor targeting Ab controls in T cell dependent fashion WT migg Wt -neu Rag -/- migg TUBO derived from MMTV-Rat neu Tg: oncogenic signaling dependent 75 5 Rag -/- -neu Rag-1+Ab Days after tumor inoculation * Wt+Ab Similar T cell dependency is observed using TKI: 1% relapse in Rag-1 KO mice But % in WT mice Are T cells essential for Ab-mediated tumor regression? Nature Med, 27, Cancer Cell, 21 and 214; CCR 213, Mol. Ther
5 How do antibodies trigger immune response? Anti-EGFR or anti-her2/neu CD8 ADCC cytokines IFN Increased Cross-priming Stress protein or DNA TLRs? MyD88 MyD88/HMGB-1, Type I IFN, type II IFN, DC, and T cell dependent 5
6 Major Mechanism for Anti-CD2 Antibodies: Is ADCC vs CDC? ADCC vs CDC: which is more important N Engl J Med 212;366:
7 V o lu m e o f th e tu m o r(m m 3 ) V o lu m e o f th e tu m o r(m m 3 ) V o lu m e o f th e tu m o r(m m 3 ) The therapeutic effect of anti-cd2 treatment is CD8 T cell dependent A C trl A n ti-m C D 2 B C trl A n ti-m C D 2 C C trl A n ti-c D 8 A n ti-m C D 2 A n ti-m C D 2 + a n ti-c D nude T im e a fte r tu m o r in o c u la tio n (d ) T im e a fte r tu m o r in o c u la tio n (d ) T im e a fte r tu m o r in o c u la tio n (d )
8 T u m o r v o lu m e (m m 3 ) S F C s p e r 3 * 1 5 c e lls Anti-CD2 DC?? CD8 + T cell Tumor control 1.8*1 6 A2 S.C. 1μg of anti-mcd2 (Anti-mCD2) or higg (Ctrl) i.p. CD11c-DTR D12 D15 D11 DT i.p. every other day 8 h Ig G 1 h Ig G 1 + D T A n ti-m C D 2 6 A n ti-m C D 2 + D T h Ig G 1 A n ti-m C D 2 h Ig G 1 + D T 1 5 A n ti-m C D 2 + D T T im e a fte r tu m o r in o c u la tio n (d ) M e d iu m A 2 DC is necessary for anti-cd2 treatment 8
9 T u m o r v o lu m e (m m 3 ) S F C s p e r 2 *1 5 c e lls The therapeutic function of anti-cd2 is macrophage-dependent 1.8*1 6 A2 S.C. 1μg of anti-mcd2 BALB/c D12 D15 D11 Clophosome i.p. twice a week D26 IFN-γ ELISPOT 1 C trl C lo p h o s o m e A n ti-m C D 2 8 A n ti-m C D 2 + C lo p h o s o m e 5 4 P <. 1 C trl A n ti-m C D 2 C trl + C lo p h o s o m e 6 3 A n ti-m C D 2 + C lo p h o s o m e T im e a fte r tu m o r in o c u la tio n (d ) M e d iu m A 2 9 How can both DC and macrophages are essential?
10 IF N - (p g /m l) Anti-CD2 induced increase of DC cross-presentation is macrophage-dependent Isolated DCs from A2-HA-bearing mice treated with anti-cd2 +/- MO CL4 T cells P <. 5 Cross priming IFNg MO dep. IF N (p g /m l) Isolated cell For type I IFN C trl P <. 1 A n ti-m C D 2 S F C s p e r 3 *1 5 c e lls 6 C trl 4 2 T cell responses are IFNRA dependent A n ti-m C D 2 P =. 1 A n ti-m C D 2 + a n ti-ifn a r1 C trl A n ti-m C D 2 A n ti-m C D 2 + C lo p h o s o m e D C M a c ro p h a g e D C M a c ro p h a g e M e d iu m A 2 Anti- CD2 Mɸ IFN-I DC CD8 + T cell Tumor control 1
11 CD47 blockade permits rapid phagocytosis of tumor cells: Innate checkpoint blockade? Do not eat me CD47 is innate checkpoint that prevent phagocytosis Eat me signals NSG mice Cell, 29 ALL model Blood; 71(4);
12 Tumor volume(mm 3 ) Tumor volume (mm 3 ) T u m o r v o lu m e (m m 3 ) T u m o r v o lu m e (m m 3 ) Tumor volume (mm 3 ) T cells are essential for anti-cd47-mediated tumor control in syngenic tumor models A2 (lymphoma) systemic local MC38(colon cancer) a A 2 (i.p. a n ti-c D 4 7 ) R a tig a n ti-c D ra tig G a n ti-m C D 4 7 c c RatIg anti-cd D a y s a fte r tu m o r in o c u la tio n * 4 2 * D a y s a fte r tu m o r in o c u la tio n 2 ** Days after tumor inoculation d Nude ratigg Nude anti-mcd47 ns Days after tumor inoculation e RatIg anti-mcd47 Nude mice Days after tumor inoculation *
13 Tumor volume (mm 3 ) But the protection of anti-cd47 Ab is dependent on CD8 T cells A: CD8 dependent B: memory response by rechallenge Naive anti-cd Days after tumor rechallenge 13
14 Therapeutic effect of anti-cd47 depends on type I IFNs and DC responding to IFN for cross priming. re la tiv e c o p y n u m b e (x 1-3 ) Tumor volume (mm 3 ) Tumor volume (mm 3 ) A: IFN production by DC M o n o c y te IF N R a tig a n ti-c D 4 7 * ns M a c ro p h a g e * * D C B: IFNAR signaling RatIg anti-ifnar anti-cd47 anti-cd47+anti-ifnar Days after tumor inoculation C: IFNAR on DC ** CD11c-cre x IFNAR fl/fl = no IFNAR on DC Ifnar1 fl/fl +RatIg Ifnar1 fl/fl + anti-cd47 Cd11c cre Ifnar1 fl/fl + RatIg Cd11c cre Ifnar1 fl/fl + anti-cd47 ** Days after tumor inoculation Which pathway to produce IFN: MyD88, like anti-neu? 14
15 Tumor size (mm 3 ) Tumor volume (mm 3 ) Neither MyD88 nor Trif, two major pathways for IFN production, is essential for tumor control by anti-cd47 1 RatIg 8 anti-cd47 MyD88 -/- +RatIg 6 MyD88 -/- +anti-cd RatIg anti-cd47 Trif-/-+RatIg Trif-/-+anti-CD47 2 ns 2 ns Days after tumor inoculation Days after tumor inoculation Xu et al Nature Med
16 Tumor volume (mm 3 ) Fold induction IFN- spots/1 6 cells STING signaling is essential for type I IFNs Sting dependent: tumor control DC IFN production Cross-Priming c d e 8 RatIg anti-cd47 6 Sting mut +RatIg Sting mut +anti-cd * IFN * RatIg anti-cd47 CD8 T cells response 2 RatIg 15 *** *** anti-cd * 2 ns Days after tumor inoculation WT Sting mut WT Sting mut 16
17 Tumor size (mm 3 ) Tumor size (mm 3 ) STING from DC but not macrophages is required for anti-cd47 therapy A B 15 Sting f/f +rat Ig Sting f/f +anti-mcd47 1 Lyz-cre;Sting f/f +rat Ig Lyz-cre;Sting f/f 5 +anti-mcd47 ** ns 2 Sting f/f +rat Ig Sting f/f +anti-mcd47 15 Cd11c-cre;Sting f/f +rat Ig 1 Cd11c-cre;Sting f/f +anti-mcd47 5 ns *** Days after tumor inoculation Days after tumor inoculation Why can DC but not macrophages be essential for innate sensing? Which type of DNA or DNA complex senses cgas/sting pathway? 17
18 % of EdU + cells Anti-CD47 increases DNA and tumor uptake by both DC and macrophages CFSE-labeled MC38 tumor cells + BMDC or BMM Ab 1 h. A Edu labeled tumor cells were inoculated Ab 4 h cells harvested Gate: CD45+CD11b+: Increased DNA uptake by anti-cd47 B 15 1 RatIg anti-cd47mab ** * 5 BMDC BMM
19 Cytosolic DNA (Relative copy number) Fold Change (relative to RatIg) DCs accumulate more cytosolic DNA after CD47 blockade ex vivo 3 *** *** 2 RatIg Anti-mCD47(24h) Anti-mCD47(72h) Cytosolic mtdna Rat Ig Anti-mCD47 ** 1 2 gdna mtdna Mono M DC
20 Anti-CD47 promotes tumor-derived mtdna Cytosolic DNA (Relative copy number) Cytosolic DNA (Relative copy number) Host VS Tumor? Genomic DNA VS Mitochondrial DNA? gdna mtdna 8 RatIg Anti-mCD mig ** Anti-hCD ns mouse ns human 2 ns mouse human
21 IFN- spots/1 6 cells DNA abundance (%) Fold Change (relative to RatIg) Tumor mtdna is required for type I IFN production and cross-priming in DC A DDC reduces mtdna B: 1 ns *** Non-ddC ddc 6 4 IFN- * Rat Ig Anti-mCD ns gdna mtdna mtdna depleted Macrophage DC C 6 4 *** *** Rat Ig Anti-mCD47 2 mtdna depleted ns
22 Phagosomal PH Phagosomal PH Phagosomal mtdna (relative to RatIg) CD47-SIRPα signaling in DCs controls the phagosomal PH and DNA degradation A: mtdna reduced in macrophages but not DC 3 ** ns RatIg ** ** anti-cd47(') anti-cd47(3') 2 anti-cd47(9') 1 Macrophage DC B: ph in macrophage is reduced C: ph in DC increase Macrophage 5 M alone M +Tumor(ratIg) 4 M +Tumor(anti-CD47) Time of chase (min) 8 7 DC 6 DC alone 5 DC+Tumor(ratIg) DC+Tumor(anti-CD47) Time of chase (min) *
23 Tumor Volume (mm 3 ) Tumor Volume (mm3) T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) % C D 3 + C D 8 + in tu m o r Cell counts CD47 on tumor cells plays dominate role in evasion and PD-L1 is an adaptive resistance A B C D M C 3 8 M C 3 8 -C D 4 7 K O * M C 3 8 M C 3 8 -C D 4 7 K O M C 3 8 -C D 4 7 K O + a n ti-c D 8 * * * 4 3 * * * ISO MC38 MC38-CD47 KO 5 * * * * T im e a fte r tu m o r in o c u la tio n (d a y ) T im e a fte r tu m o r in o c u la tio n (d a y ) M C 3 8 M C 3 8 -C D 4 7 K O PDL1 E MC38 MC38-CD47 KO MC38-PDL1 KO MC38-CD47/PDL1 DKO *** F WT:MC38 WT:MC38-CD47/PDL1 DKO Rag-/-:MC38 Rag-/-:MC38-CD47/PDL1 DKO *** G 1 5 M C 3 8 M C 3 8 -C D 4 7 /P D L 1 D K O M C 3 8 -C D 4 7 /P D L 1 D K O + a n ti-c D 8 * * Time after tumor inoculation (day) Time after tumor inoculation (day) T im e a fte r tu m o r in o c u la tio n (d a y )
24 T u m o r V o lu m e (m m 3 ) IFNAR and STING/IFN on host cells are required for CD47 /PDL1-mediated evasion T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) A W T :M C 3 8 W T :M C 3 8 -C D 4 7 /P D L 1 D K O IF N A R -/-:M C 3 8 IF N A R -/-:M C 3 8 -C D 4 7 /P D L 1 D K O B W T :M C 3 8 W T :M C 3 8 -C D 4 7 /P D L 1 D K O S T IN G m u t :M C 3 8 S T IN G m u t :M C 3 8 -C D 4 7 /P D L 1 D K O 1 * * * * * * * T im e a fte r tu m o r in o c u la tio n (d a y ) C T im e a fte r tu m o r in o c u la tio n (d a y ) W T :M C 3 8 W T : M C 3 8 -C D 4 7 /P D L 1 D K O C D 1 1 C -S T IN G -/-:M C 3 8 C D 1 1 C -S T IN G -/-:M C 3 8 -C D 4 7 /P D L 1 D K O 1 5 * * * * T im e a fte r tu m o r in o c u la tio n (d a y )
25 Binding RBC is the major barrier for systemic use of anti-cd47 How can we target tumor better? A B RBC MC38 SIRPa anti-pdl1-sirpa Tumor cells have both PD-L1 and CD47 while RBC have only CD47. Bi-specific anti-pdl1-sirpα maintaining binding to tumor cells while greatly reducing binding to RBC
26 T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) Co-targeting of CD47 and PDL1 on tumor cells is required for tumor growth inhibition A In tra tu m o ra l tre a tm e n t B S y s te m ic tre a tm e n t h Ig G a n ti-p D L 1 S IR P a a n ti-p D L 1 -S IR P a h Ig G a n ti-p D L 1 -S IR P a a n ti-p D L 1 + S IR P a 5 * * * 1 5 * * D 1 5 T im e a fte r tu m o r in o c u la tio n (d a y ) M C 3 8 -C D 4 7 K O tu m o r E 1 5 T im e a fte r tu m o r in o c u la tio n (d a y ) M C 3 8 -P D L 1 K O tu m o r 1 h Ig G a n ti-p D L 1 -S IR P a 1 h Ig G a n ti-p D L 1 -S IR P a T im e a fte r tu m o r in o c u la tio n (d a y ) T im e a fte r tu m o r in o c u la tio n (d a y )
27 T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) Anti-PDL1-SIRPα enhances intratumoral DC innate sensing 1 8 W T : h Ig G W T : a n ti-p D L 1 -S IR P a S T IN G -/-: h Ig G S T IN G -/-: a n ti-p D L 1 -S IR P a 1 5 S T IN G -/-: h Ig G S T IN G -/-: a n ti-p D L 1 -S IR P a C D 1 1 c -S T IN G -/-: h Ig G C D 1 1 c -S T IN G -/-: a n ti-p D L 1 -S IR P a * 5 * T im e a fte r tu m o r in o c u la tio n (d a y ) T im e a fte r tu m o r in o c u la tio n (d a y )
28 Summary Therapeutic effect of anti-cd47 depends on CTL. DCs but not macrophage are required for anti-cd47 Abmediated cross priming While macrophages degrade DNA faster than DC Anti-CD47 Ab-mediated type I IFN induction or cross priming by host DC depends on cgas-sting pathway DC can better sense cytosol mtdna through cgas-sting pathway 28
29 Acknowledgements: CAS collaborative group Radiation Liufu Deng Sog Auh/Youjin Lee Byron Burnette Anti-CD47 Ab Michelle Xu Xiaojuan Liu Christine Pu Hua Peng Anti-Neu SeaGwang Park Yang Wang Eric Morterson Shengdien Wang Ab-IFN Xuanming Yang Yang Wang Ab-LIGHT Haidong Tang Yang Wang CD2 Zhenhua Ren Hua Peng UC Ralph Weichselbaum Tom Gajewski Hans Schreiber UTSW Zhijian James Chen Alphamab Luan Yan Ting Xu 29
30 T u m o r v o lu m e (m m 3 ) Large tumors have more CTLA+ Treg and resist to anti- CD2 therapy: new strategy for combination 2 5 h Ig G + h a m s te r Ig G A n ti-m C D 2 + h a m s te r Ig G 2 A n ti-c T L A -4 + h Ig G A n ti-m C D 2 + a n ti-c T L A T im e a fte r tu m o r in o c u la tio n (d ) Anti-CTLA4 therapy overcomes anti-cd2 resistance 3
31 P e rc e n t s u rv iv a l Cell counts P e rc e n t s u rv iv a l Pretreatment with chemotherapy induces more eat me signal and synergize with anti-pdl1-sirpα for tumor eradication A B 1 h Ig G * D O X a n ti-p D L 1 -S IR P a D O X + a n ti-p D L 1 -S IR P a 5 Calreticulin T im e a fte r tu m o r in o c u la tio n (d a y ) C 1 h Ig G D O X + a n ti-p D L 1 -S IR P a * * Z -V A D -F M K Z -V A D -F M K + D O X + a n ti-p D L 1 -S IR P a T im e a fte r tu m o r in o c u la tio n (d a y )
32 IF N -r s p o ts /1 6 c e lls Tumor Volume (mm3) T u m o r V o lu m e (m m 3 ) T u m o r V o lu m e (m m 3 ) CD8 + T cells are essential for the therapeutic effect of anti-pdl1-sirpα A h Ig G R a g -/- a n ti-p D L 1 -S IR P a B h Ig G a n ti-p D L 1 -S IR P a a n ti-c D 8 a n ti-p D L 1 -S IR P a + a n ti-c D * * * T im e a fte r tu m o r in o c u la tio n (d a y ) T im e a fte r tu m o r in o c u la tio n (d a y ) C 3 * 2 * D 15 1 higg anti-pdl1-sirpa FTY72 anti-pdl1-sirpa+fty ns h Ig G a n ti-p D L 1 S IR P a a n ti-p D L 1 -S IR P a Time after tumor inoculation (day)
33 Is Tumor expressed-pdl1 essential for tumor growth or PD-L1 blockade therapy? No and no Generate PD-L1 KO tumor PD-L1 from host cells but not tumor is essential for suppression 33
34 Type I IFN is essential for various anti-cancer therapy induced tumor regression: such as RT, anti-her2/neu, anti-cd47 and some chemo drugs IFN has been used in some cancer therapy to suppress tumor cell proliferation Can tumor targeting antibodies bring sufficient IFN to tumor tissues for immune responses:? 34
Supplementary figure 1. Systemic delivery of anti-cd47 antibody controls tumor growth in
T u m o r v o lu m e (m m 3 ) P e rc e n t s u rv iv a l P e rc e n t s u rv iv a l Supplementary data a 1 8 6 4 2 5 1 1 5 2 2 5 3 3 5 4 T im e a fte r tu m o r in o c u la tio n (d ) b c 1 5 1 1 5 * *
More informationSupplemental Information. The Therapeutic Effect. of Anti-HER2/neu Antibody Depends. on Both Innate and Adaptive Immunity CONTENTS:
Cancer Cell, Volume 18 Supplemental Information The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity SaeGwang Park, Zhujun Jiang, Eric D. Mortenson, Liufu Deng,
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationWIN 2015 Symposium Radiation and immunology: a new therapeutic partnership
WIN 215 Symposium Radiation and immunology: a new therapeutic partnership Dr. Ralph Weichselbaum Conflict of Interest Nothing to Disclose Limitations of Radiotherapy Radiotherapy cannot be given in high
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/8/333/333ra47/dc1 Supplementary Materials for Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor
More informationCD47 blockade triggers T cell mediated destruction of immunogenic tumors
a r t i c l e s CD47 blockade triggers T cell mediated destruction of immunogenic tumors Xiaojuan Liu 1,2,6, Yang Pu 3, Kyle Cron 3, Liufu Deng 3, Justin Kline 4, William A Frazier 5, Hairong Xu 1, Hua
More informationInnate immune regulation of T-helper (Th) cell homeostasis in the intestine
Innate immune regulation of T-helper (Th) cell homeostasis in the intestine Masayuki Fukata, MD, Ph.D. Research Scientist II Division of Gastroenterology, Department of Medicine, F. Widjaja Foundation,
More informationTargeting the Tumor Microenvironment with Interferon-b Bridges Innate and Adaptive Immune Responses
Article Targeting the Tumor Microenvironment with Interferon-b Bridges Innate and Adaptive Immune Responses Xuanming Yang, 1,2,5 Xunmin Zhang, 1,3,5 May Lynne Fu, 2 Ralph R. Weichselbaum, 4 Thomas F. Gajewski,
More informationPersonalized Cancer Neoantigen Vaccines
Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,
More informationFelix Yarovinsky. Department of Immunology, UT Southwestern Medical Center. Innate immune defense to Toxoplasma gondii
Felix Yarovinsky Department of Immunology, UT Southwestern Medical Center Innate immune defense to Toxoplasma gondii Pathogen recognition by innate immune cells Pathogen Parasites Viruses Bacteria Initiator
More informationTargeting CD47 to involve macrophages and dendritic cells in a holistic anti-tumor immune response
Targeting CD47 to involve macrophages and dendritic cells in a holistic anti-tumor immune response Marie Kosco-Vilbois, PhD CSO Novimmune SA 1 CD47 is an immune checkpoint receptor Cell Macrophage Activating
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver
More informationSupplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.
A B16F1 s.c. Lung LN Distant lymph nodes Colon B B16F1 s.c. Supplementary Figure 1. Deletion of Smad3 prevents B16F1 melanoma invasion and metastasis in a mouse s.c. tumor model. Highly invasive growth
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationCELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION
CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION Justin Kline 1, Long Zhang 1, and Thomas F. Gajewski 1,2 Departments
More informationSTING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Article STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors Liufu Deng, 1,3 Hua Liang, 1,3 Meng Xu, 2 Xuanming Yang, 2
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/8/352/352ra110/dc1 Supplementary Materials for Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
More informationNature Medicine: doi: /nm.3922
Title: Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells Authors: Il-Kyu Kim, Byung-Seok Kim, Choong-Hyun
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationNovel Approaches to CAR-T Cell Platform
Novel Approaches to CAR-T Cell Platform Vita Golubovskaya, Ph.D. Director, R&D Promab Biotechnologies 3 rd CAR-TCR Summit 2017 S E P T E M B E R 5-7 B O S T O N Novel Approaches To CAR-T Cell Platform
More informationPreclinical Assessment of JTX-2011, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial
Preclinical Assessment of JTX-211, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial Jennifer Michaelson, Ph.D. AACR Annual Meeting April 2, 217 Major Symposium Emerging
More informationGamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells
Gamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells Gérald J. Prud homme, MD, FRCPC Keenan Research Centre for Biomedical
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationIntracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining Btk activation Xingguang Liu, Zhenzhen Zhan, Dong Li, Li Xu, Feng Ma, Peng Zhang, Hangping Yao and Xuetao
More informationCell-mediated Immunity
Cellular & Molecular Immunology Cell-mediated Immunity Nicholas M. Ponzio, Ph.D. Department of Pathology & Laboratory Medicine April 6, 2009 Today s Presentation: Overview Cellular Interactions In Humoral
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationThe Ying and Yang of IFN-γ in Autoimmunity
The Ying and Yang of IFN-γ in Autoimmunity Chander Raman, Ph.D. Early Late Autoimmune neuroinflammation Experimental autoimmune encephalomyelitis (EAE) Rheumatoid arthritis (RA) Autoimmune neuroinflammation
More informationSupplemental Materials
Supplemental Materials Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability Qi Wang 1, Jianwei He 1, Dallas B. Flies 2, Liqun Luo
More informationLDR and its potential application in clinics
LDR and its potential application in clinics Lu Cai Departments of Medicine & Radiation Oncology University it of Louisville School of Medicine LDR effects Hormesis Adaptive response Bystander effects
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationIdentification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationDual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast NALM-6 tumor cells (B-ALL) Human macrophages
Dual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast Krzysztof Masternak, PhD, Head of Biology 1 2 nd Biologics & BOARD Biosimilars MEETING Congress MARCH 2012 NALM-6
More informationRegulatory B cells in autoimmunity. Liwei Lu University of Hong Kong, China
Regulatory B cells in autoimmunity Liwei Lu University of Hong Kong, China Multiple functions of B cells in immunity LeBien and Tedder, Blood (2008) B cell functions in autoimmune pathogenesis The Immunopathogensis
More informationUnderstanding the T cell response to tumors using transnuclear mouse models
Understanding the T cell response to tumors using transnuclear mouse models Stephanie Dougan Dana-Farber Cancer Institute Boston, MA Presenter Disclosure Information Stephanie Dougan The following relationships
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationIMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, psoriasis
IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in mouse models of psoriasis Weiwen e Ja Jiang, Fu-Gang Zhu, Dong Yu, Ekambar R. Kandimalla, a a, Nicola La Monica, and Sudhir
More informationSupplementary Figure 1. Characterization of basophils after reconstitution of SCID mice
Supplementary figure legends Supplementary Figure 1. Characterization of after reconstitution of SCID mice with CD4 + CD62L + T cells. (A-C) SCID mice (n = 6 / group) were reconstituted with 2 x 1 6 CD4
More informationDendritic cells in cancer immunotherapy Aimin Jiang
Dendritic cells in cancer immunotherapy Aimin Jiang Feb. 11, 2014 Dendritic cells at the interface of innate and adaptive immune responses Dendritic cells: initiators of adaptive immune responses Dendritic
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationUnderstanding and overcoming immunoregulatory barriers within
Understanding and overcoming immunoregulatory barriers within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and
More informationManipulating the Tumor Environment
Manipulating the Tumor Environment Vincenzo Bronte Verona University Hospital vincenzo.bronte@univr.it Escape from immune control can be viewed as one of the «Hallmarks of Cancer» D. Hanahan and R. A.
More informationImmunotherapy in Lung Cancer - TLR9 as a therapeutic target -
Immunotherapy in Lung Cancer - TLR9 as a therapeutic target - Wilfried Eberhardt,, MD Head of Outpatient Unit, Dept. of Internal Medicine (Cancer Research) West German Cancer Centre Essen University Hospital
More informationSUPPLEMENTARY INFORMATION
Table S1: Combination Immunotherapy: Small Molecules that Boost Immune Response in Combination with Other Agents Target Compound (MOA) NLG919 and indoximod 1- MT Combination Model Observation Reference
More informationSupplementary Figure 1
Supplementary Figure 1 YAP negatively regulates IFN- signaling. (a) Immunoblot analysis of Yap knockdown efficiency with sh-yap (#1 to #4 independent constructs) in Raw264.7 cells. (b) IFN- -Luc and PRDs
More informationTargeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018
Targeting tumour associated macrophages in anti-cancer therapies Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018 Macrophages: Professional phagocytes of the myeloid lineage APC,
More informationSupplemental Materials for. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to. FTY720 during neuroinflammation
Supplemental Materials for Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY7 during neuroinflammation This file includes: Supplemental Table 1. EAE clinical parameters of
More informationIrradiation and anti PD-L1 treatment synergistically promote antitumor immunity in mice
Research article Irradiation and anti PD-L1 treatment synergistically promote antitumor immunity in mice Liufu Deng, 1 Hua Liang, 1 Byron Burnette, 1 Michael Beckett, 1 Thomas Darga, 1 Ralph R. Weichselbaum,
More informationImmune Regulation and Tolerance
Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationSupplementary information
Supplementary information Intrahepatic myeloid cell-aggregates enable local CD8 + T cell expansion and successful immunotherapy against chronic viral liver infection Li- Rung Huang, Dirk Wohlleber, Florian
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationErbb2 transgenic mice: a tool to evaluate the potential efficacy of vaccination in the prevention and cure of carcinomas
1 st International MUGEN Conference on Animal Models for Human Immunological Disease Athens, 11 September 2006 Erbb2 transgenic mice: a tool to evaluate the potential efficacy of vaccination in the prevention
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationHua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I Nakaya, Kousik
SUPPLEMENTARY FIGURES 1-19 T H 2 response to cysteine-proteases requires dendritic cell-basophil cooperation via ROS mediated signaling Hua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder
More informationRestoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma
Restoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma Goding SR et al. J Immunol 2013; 190:4899-4909 C. Nikolowsky Christian Doppler Laboratory for Cardiac and Thoracic
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationRationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy
Society for Immunotherapy of Cancer (SITC) Rationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy Qing Yi, MD, PhD Staff and Chair, Department of Cancer Biology Betsy B. DeWindt Endowed
More informationSupplemental Figure 1. Protein L
Supplemental Figure 1 Protein L m19delta T m1928z T Suppl. Fig 1. Expression of CAR: B6-derived T cells were transduced with m19delta (left) and m1928z (right) to generate CAR T cells and transduction
More informationNature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.
Supplementary Figure 1 Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice. (a) Gene expression profile in the resting CD4 + T cells were analyzed by an Affymetrix microarray
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationImmunity to Bodetella pertussis. Kingston Mills. Trinity Biomedical Sciences Institute Trinity College Dublin, Ireland
Immunity to Bodetella pertussis Kingston Mills Trinity Biomedical Sciences Institute Trinity College Dublin, Ireland Correlates / mechanisms of immunity Vaccine/ Infection Efficacy in Children Efficacy
More informationRichard S. Kornbluth, M.D., Ph.D.
Treatment of established tumors with peritumoral injections of CD40 ligand (CD40L), CpG, poly(i:c), and extracellular ATP in murine models Richard S. Kornbluth, M.D., Ph.D. Disclosure: Richard Kornbluth
More informationThe Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
rticle The Therapeutic Effect of nti-her2/neu ntibody Depends on oth Innate and daptive Immunity SaeGwang Park, 1,2,3,6 Zhujun Jiang, 1,6 Eric D. Mortenson, 2,6 Liufu Deng, 1 Olga Radkevich-rown, 2 Xuanming
More informationEvidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials
PV-10 Moves Forward-1 Evidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials At the same time that current research projects are solidifying and reinforcing the evidence for PV-10 s systemic
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-12-1-0344 TITLE: Targeting Immunological "Restrainers": Understanding the Immunology behind Combination Chemoimmunotherapy to Improve the Treatment of Malignant Mesothelioma PRINCIPAL
More informationSupplemental Materials. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in. Pancreatic Cancer.
Supplemental Materials Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer Jun Zhao 1, Zhilan Xiao 2, 3, Tingting Li 1, 4, Huiqin Chen 5, Ying Yuan 5, Alan
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationRational combinations with immunotherapeutics
Rational combinations with immunotherapeutics Ronald Levy, MD Robert K. and Helen K. Summy Professor of Medicine Director, Lymphoma Program Stanford University School of Medicine Associate Director, Translational
More informationCetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
The American Society of Gene & Cell Therapy original article Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses Xuanming Yang 1,2, Xunmin Zhang 2,3, Eric D Mortenson 2,
More informationGene+c fate mapping. x loxp. Foxp3 3 UTR ROSA26 RFP IRES GFP CRE. STOP loxp. Stable Foxp3 expression. Foxp3 expression in new Treg.
1 Introduc+on (CD4 + CD25 + Foxp3 + )are indispensable for immune homeostasis. Muta+ons in Foxp3 gene leads to fatal autoimmune disorder. Condi+onal dele+on of Foxp3 reprograms cells into pathogenic Th
More informationIntegrin CD11b negatively regulates TLR-triggered inflammatory responses by. activating Syk and promoting MyD88 and TRIF degradation via cbl-b
Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting MyD88 and TRIF degradation via cbl-b Chaofeng Han, Jing Jin, Sheng Xu, Haibo Liu, Nan Li, and Xuetao
More informationSupplementary information. Characterization of c-maf + Foxp3 - Regulatory T Cells Induced by. Repeated Stimulation of Antigen-Presenting B Cells
Chien 1 Supplementary information Manuscript: SREP-16-42480A Characterization of c-maf + Foxp3 - Regulatory T Cells Induced by Repeated Stimulation of Antigen-Presenting B Cells Chien-Hui Chien 1, Hui-Chieh
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationUtilizing Humanized NSG Mice to Evaluate Drug Efficacy in Immuno-Oncology
Utilizing Humanized NSG Mice to Evaluate Drug Efficacy in Immuno-Oncology Rick Huntress Director Business Development March 15, 2017 Onco-Hu : Humanized Mice for Evaluation of Immuno-Oncology Therapeutics
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More informationIn-San Kim, M.D., Ph.D. KIST InterMembrane Signaling Lab & KU-KIST, Korea University The 15 th Korea-US Forum on Nanotechnology,
In-San Kim, M.D., Ph.D. KIST InterMembrane Signaling Lab & KU-KIST, Korea University The 15 th Korea-US Forum on Nanotechnology, 2018. 7. 12 Annals of Oncol. 2018 Tang et al., 2004 new IO agents : 940
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationPutting it Together. Stephen Canfield Secondary Lymphoid System. Tonsil Anterior Cervical LN s
Putting it Together Stephen Canfield smc12@columbia.edu Secondary Lymphoid System Tonsil Anterior Cervical LN s Axillary LN s Mediastinal/Retroperitoneal LN s Thoracic Duct Appendix Spleen Inguinal LN
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationTargeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases
This information is current as of October 6, 2018. References Subscription Permissions Email Alerts Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases Ping
More informationApproved for Public Release; Distribution Unlimited
AD Award Number: W81XWH-04-1-0186 TITLE: A Novel Therapeutic System for the Treatment of Occult Prostate Cancer PRINCIPAL INVESTIGATOR: Shongyun Dong, M.D., Ph.D. CONTRACTING ORGANIZATION: University of
More information1. Background and Significance Currently there are no efficacious therapies for renal cell carcinoma (RCC). Despite recent
1. Background and Significance Currently there are no efficacious therapies for renal cell carcinoma (RCC). Despite recent advances in development of protective immune-based therapies for RCC, the prognosis
More informationLicia Rivoltini, MD Unit of Immunotherapy of Human Tumors
Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors The complex network of anti-tumor immunity Innate immunity First line defense Tumor cell Adaptive immunity Specificity & memory Kidd et al., Nature
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationFcγRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via ipilimumab-dependent ADCC in melanoma patients
FcγRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via ipilimumab-dependent ADCC in melanoma patients Emanuela Romano Department of Oncology University of Lausanne and
More informationImmunologic Effects of Clinical Stage FAK & PI3K-Delta/Gamma Inhibitors
1 Immunologic Effects of Clinical Stage FAK & PI3K-Delta/Gamma Inhibitors Jonathan Pachter, Ph.D - Chief Scientific Officer 3rd Annual Immuno-Oncology Congress, May 24, 2018 Disclosures 2 I am an employee
More informationCanberra, Australia). CD11c-DTR-OVA-GFP (B6.CD11c-OVA), B6.luc + and. Cancer Research Center, Germany). B6 or BALB/c.FoxP3-DTR-GFP mice were
Supplemental Materials and Methods Mice Female C57BL/6 (B6, I-E null, H-2 b ), BALB/c (H-2 d ) + ), FVB/N (H-2 q, I-E null, CD45.1 + ), and B6D2F1 (H-2 b/d ) mice were purchased from the Animal Resources
More information8/3/2016. Why are abscopal effects of radiation so rare? Radiation therapy to ignite an anti-cancer immune response DISCLOSURES
8/3/216 Radiation therapy to ignite an anti-cancer immune response Silvia Formenti, M.D. Weill Cornell Medical College New York Presbyterian Hospital New York, NY DISCLOSURES Consultant/Speaker: Bristol
More informationEnhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington
Enhancing the Clinical Activity of HER2/neu Specific T Cells William Gwin, MD Internal Medicine, Resident University of Washington Immunotherapy and Cancer Cancer vaccines were originally used in melanoma
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited
AD (Leave blank) Award Number: W81XWH-07-1-0345 TITLE: Second-Generation Therapeutic DNA Lymphoma Vaccines PRINCIPAL INVESTIGATOR: Larry W. Kwak, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Texas
More informationCross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality
Article Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality Graphical Abstract Authors Xiao Yu, Baowei Cai, Mingjun
More information